StockWatch
·

Emcure Pharmaceuticals Ltd Q2 FY27 Results

EMCUREQ2 FY27 Results
Filing
Result:Very Good· Market: Up#Broad based#Margin expansion

Outlook: Optimistic · Guidance: Raised

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue2.8K9.3%24.3%
Total Income2.8K9.3%24.2%
Expenditure2.4K8.6%23.1%
PBT445.8513.3%30.6%
Net Profit325.0711.1%29.3%
OPM20.84%0.20pp0.11pp
NPM11.51%0.18pp0.45pp
EPS17.1610.7%33.5%
View full financials

Pharma: 24.3% YoY revenue growth with EBITDA margin up ~103bps and clean 29.3% adjusted PAT growth, driven broadly by international (+34.5%) and domestic (+12%) segments with no one-off items, marking a standout quarter for the sector.

EMCURE PHARMACEUTICALS · Q2 FY-2027 · THE VERDICT

24% growth & guidance raised — but the stock is priced for perfection at overbought levels

Guidance raised to >20% growth on a delivered 24% beat, international momentum, and 100 bps margin expansion. The real story: domestic growth slowed to 12% as Zuventus stabilizes, and the stock (RSI 76.4, +69% YTD) has priced all of this in hard.

06 Nov 2026 · 6 min read

The quarter at a glance

Revenue

₹2,820.5 Cr

+24.3% YoY, +9.3% QoQ

PAT

₹325.1 Cr

+29.3% YoY, +11.1% QoQ

EBITDA margin

20.4%

+100 bps YoY, +70 bps QoQ

NPM

11.5%

+45 bps YoY

Emcure delivered a clean quarter: revenue and profit beat prior guidance, margins expanded 100 basis points, and management raised full-year guidance from low-to-mid-teens to exceed 20%. The profit is organic — no one-time gains, no MTM cushions. But the headline masks a critical divergence: international revenue surged 34.5% YoY, while domestic growth slowed to 12% as Zuventus, the domestic-focused acquisition from Q4 FY26, stabilized after a management exodus and customer exodus. International is now 59% of sales and firing; domestic is struggling. For equity holders, the question is whether >20% growth can be sustained for another two quarters when one of the two engines is clearly at reduced throttle.

Where the growth came from — and where it didn't

Q2 FY27 revenue breakdown: international driving the headline; domestic acting as a brake
SegmentQ2 RevenueYoY Growth% of Total
International₹1,665 Cr+34.5%59%
Domestic (India)₹1,155 Cr+12%41%
Total₹2,820.5 Cr+24.3%100%

The decomposition exposes the vulnerability. International revenue — driven by 20+ product approvals in Q2 (liposomal amphotericin B in Brazil & Mexico, bevacizumab wet-AMD in India, trepostinilII in Europe) — is on fire. Europe grew 36% YoY; Canada +24%; rest of world +41%. But international alone is 59% of sales; if it slows, the blended growth falls fast. Domestic, at 12% YoY, is held back by Zuventus consolidation. Management flagged Zuventus as roughly 25% of total revenues; post-exodus stabilization is keeping it to low-double-digit growth, in-line with the broader IPM (India pharma market) expansion rate. The narrative from the call was 'H2 expected strong vs. prior year' — but that's a low bar (comparison to a weak year) and no acceleration is promised.

What changed on this call

  • Revenue guidance raised: FY27 now >20% (vs prior low-to-mid-teens, i.e., 10–15%). Q2 delivered 24% YoY; H1 at +23.6%. Management confident H2 continuation is credible if international approvals ramp as planned.

  • EBITDA margin guidance upside: Prior 70–100 bps expansion for FY27; Q2 alone delivered 100 bps. Management now expects 'upper end' (likely 75–100 bps), and H1 margin is 20% (+80 bps YoY). Mix, leverage, and productivity all contributing.

  • Domestic headwind explicit: Domestic +12% YoY (vs 24% blended). Zuventus stabilizing, not accelerating. Management expects H2 'in-line with IPM,' not a step-change. This is a moderately bullish framing but not a growth driver.

  • Net debt up ₹263 Cr YTD: Acquisition-driven (Canada finalization ₹551 Cr, Genova minority, U.K. product portfolio). FY28 net-cash target maintained; not a core operational risk, but capex and integration visibility are key.

Claims management made on the call — and what holds up

Earnings call claims vs. delivered results

Revenue 24% YoY to ₹2,820 Cr

Supported

Delivered ₹2,820.5 Cr, +24.3% YoY

PAT 29% YoY to ₹325 Cr

Supported

Delivered ₹325.1 Cr, +29.3% YoY

EBITDA margin expansion ~100 bps to 20.4%

Supported

EBITDA ₹575 Cr, margin 20.4%, +100 bps YoY

International revenue +34.5%, 59% of total

Supported

₹1,665 Cr Int'l, +34.5%, 59% of ₹2,820.5 Cr

20+ product approvals in Q2

Supported

Cited: amphotericin B (Brazil, Mexico), bevacizumab (India), trepostinilII (Europe), +others

FY27 guidance >20% (raised from mid-teens)

Supported

Prior 10–15%, now >20% on delivered 24%

The bull case

International scale is real and accelerating. 59% of revenue growing at 34.5% YoY with no single-product concentration (ARV is 20% guidance.

Margin expansion is broad-based. 100 bps in Q2 came from business mix (international higher-margin), productivity, and operating leverage. Gross margin improved 110 bps YoY despite rising imported raw-material and freight costs — the offset came from favorable forex and volume lift. EBITDA margin at 20.4% puts FY27 'upper end' of 75–100 bps expansion within reach; H1 is already +80 bps.

Execution credibility is high. Met Q1 guidance (22.8% growth, reaffirmed low-to-mid-teens). Q2 surpassed at 24%. PAT beat at +29.3% YoY showing not just revenue beat but margin beat too. Canada acquisition (₹551 Cr finalization in H1), Genova minority, U.K. portfolio integration on track. R&D at 4% of revenue, on guidance. No capital shocks or surprises.

The bear case

Domestic growth is a structural brake. Zuventus is ~25% of revenues and post-exodus stabilization suggests it will contribute low-single-digit to low-double-digit growth, in-line with IPM. That's a drag on blended growth. If Zuventus continues to hover at 10% or declines, domestic could slip to mid-single digits in H2, pulling blended growth below the >20% target. The company gave no quantified domestic target — a sign of caution.

Emerging-market tender pressure is structural and unresolved. ARV is 50% of rest-of-world revenue; margins are lower than corporate average. Lenacapavir is the emerging-market 'next-gen' growth driver, but tender competition is intense and pricing is eroding. Management withheld specific lenacapavir revenue guidance and margin profile — a red flag for caution. If ROW tender pricing compresses further, overall international margin resilience is tested; the company's >20% growth could come with margin headwinds.

Raw material and geopolitical headwinds are rising. Imported APIs and freight costs are climbing. Q2 benefited from favorable forex, which masked input-cost inflation; management flagged H2 as 'relatively comfortable' but acknowledged 'rising input costs.' Geopolitical risks (Iran tensions escalation, Ukraine) could spike oil/freight costs sharply. No hedging strategy disclosed; upside CPI risk is unmanaged.

How the street is positioned — and what it means

Price & technicals — overbought and near ATH. Emcure closed at ₹2,212.8, just −2.36% below its all-time high of ₹2,266.4. The stock has rallied 69% off its 52-week low (₹1,306.5) and trades well above its 20-day moving average (₹1,894.14), 50-day (₹1,912.68), and 200-day (₹1,737.24). RSI at 76.4 signals overbought conditions — a yellow flag for profit-taking and exhaustion. Volume is increasing, which suggests conviction, but also suggests liquidity for sellers to exit.

Institutional ownership — rising, but not a stampede. FII ownership increased to 4.88% (up 153 bps QoQ from 3.35%); DII to 8.46% (up 236 bps from 6.10%). Institutions are adding, but the pace is incremental, not aggressive. Promoter ownership is steady at 77.83% (−4 bps QoQ), suggesting no planned capital raising or dilution.

Insider / block deal activity — a contrarian red flag. BC Investments (likely a PE fund or hedge fund) sold 9.7 million shares @ ₹1,817 per share in recent block deals. Institutional funds (HSBC MF, Axis MF, Goldman Sachs, Morgan Stanley, HDFC Life, BNP Paribas) then bought at that same ₹1,817 price. The stock is now ₹2,212.8 — a +22% rally from those transaction prices. BC's decision to trim (and the stock's subsequent rally) is a classic contrarian signal: insiders selling into strong momentum, especially near ATH, often precede corrections. The fact that institutions stepped in and are now up 22% does not negate the yellow flag — it suggests some buying pressure remains, but profit-taking risk is elevated.

Reconciliation — the market has priced in all the good news. The fundamental story (guidance raise, 24% growth, margin expansion, international momentum) is reflected in the stock's valuation (likely 35–40x FY27 PAT). At current overbought technicals (RSI 76.4, near ATH, +69% YTD) and insider selling, the risk/reward is asymmetric to the downside. The margin of safety has collapsed. For holders, this is a moment to consider profit-taking. For new buyers, the entry point is not compelling.

Risks ranked by impact on a holder

What could go wrong — ranked by severity and why it matters

Domestic growth deceleration / Zuventus stabilization stalls

High

Zuventus is 25% of revenues; post-exodus stabilization contributed only 12% growth in Q2 (vs 24% blended). If domestic slows further, blended growth drops below 20% target, and FY27 guidance is missed.

Emerging-market tender pricing compression

Medium

ARV is 50% of ROW (~15–20% of total). Lenacapavir opportunity is real but emerging-market tender pricing is commoditizing. If margins compress, the >20% growth comes with margin headwinds, not expansion.

Raw material/freight cost inflation + geopolitical shocks

Medium

Q2 benefited from favorable forex; H2 risks rising input costs and oil volatility (Iran/Ukraine scenarios). Gross margin 110 bps improvement could reverse. No hedging disclosed.

Manufacturing/regulatory delays (amphotericin B, U.K. portfolio)

Medium

2 amphotericin B sites; 18–24 months to full unrestricted capacity. Recent audits cleared, but regulatory dependencies remain. Delays would push new-product ramps into FY28, missing FY27 growth momentum.

Valuation drawdown on technical reversal

Medium

Stock is overbought (RSI 76.4, near ATH, +69% YTD). Insider selling, rising technical risk. A 15–20% pullback is possible if H2 guidance is missed or macro headwinds surface.

The debate

What to watch next — three catalysts that resolve the debate

Concrete milestones in the next 6–12 months
  • 1 · H2 FY27 domestic growth acceleration (Zuventus stabilization into ramp)

    Management expects H2 'strong vs. prior year' (low bar, year-on-year comparison). If domestic grows >15% in H2 vs 12% in Q2, it validates the stabilization-to-ramp narrative and supports >20% blended target. If domestic stays at 12% or decelerates, the Zuventus story is stalled, and FY27 misses guidance.

  • 2 · Amphotericin B Europe launch and revenue contribution (next 6–12 months)

    One of 20+ Q2 approvals. Europe is a high-margin market; U.K. & Europe approvals already secured. If amphotericin B ramps to ₹50–80 Cr annualized run-rate by Q4 FY27, it validates international growth durability. Manufacturing site audits cleared; timeline is key.

  • 3 · Semaglutiide Canada launch and Poviztra obesity market traction (FY28 signaling)

    Semaglutiide supply expected 'next few months' (Q4 FY27+); Poviztra obesity brand 'early-stage' today but a mid-term growth lever. If management guides FY28 growth >15% on these catalysts, it signals confidence in next-phase drivers. If FY28 guidance is muted, core franchises are saturating and growth is cyclical.

The honest read

Q2 was a solid beat: +24.3% revenue, +29.3% profit, +100 bps margin expansion. Management raised FY27 guidance to >20% — a credible move backed by delivered 24% and international momentum. This is NOT a step-change in the franchise; it's a steady, profitable compounder running hard on its international fuel tank. Domestic is stabilizing, not accelerating, and tender margins are under structural pressure.

The stock has priced all of this in: up 69% YTD, near ATH, overbought (RSI 76.4), with insider selling and institutional buying at lower prices followed by a 22% rally. The technical setup is stretched. For holders, the risk/reward at ₹2,212.8 favors taking profits. For new buyers, there is no margin of safety.

The single number to track from here: H2 FY27 domestic revenue growth. If it re-accelerates above 15%, the Zuventus story is working and >20% is achievable. If it stays at 12%, Emcure is international-dependent and macro-sensitive, not the premium compounder the market is pricing. That one number resolves the debate. Until then, hold on strength; do not chase at ₹2,212.

Emcure delivered, raised guidance, and proved execution. The stock has priced it all in, and insiders are trimming near the highs. Profitability is real; sustainability is unproven. Holders: take profits. Buyers: wait for a pullback.

Informational and educational content only. Not investment advice.